Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma
Status:
Unknown status
Trial end date:
2020-03-20
Target enrollment:
Participant gender:
Summary
In non-small cell lung cancer and metastases in the pleural cavity, pathological effusion is
formed.
Currently, the most common and effective method of obliteration of the pleural cavity is
pleurodesis with talcum powder.
Talc, when it surface of the pleura, causes chemical inflammation that leads to the soldering
of the lungs and chest wall. As a result, the liquid ceases to accumulate.
The addition of a therapeutic dose of afatinib to talc not only blocks effusion into the
pleural cavity, but also reduces tumor and metastatic processes.